TRENDING :  Market Movers  |  Top 50   FDX (-2.8%)    SPY (-1.93%)    AMZN (-3%)    VXXB (11.47%)    LVS (-2.67%)    MCD (0.24%)    NFLX (-4.47%)    NRG (-2.03%)    NXST (-3.18%)    PBR (-7.22%)    PEI (0.33%)    POST (-0.17%)    PYPL (-2.77%)    QQQ (-2.2%)    ROKU (-4.53%)    SBUX (-0.42%)    SCIF (-3.28%)    SLNO (2.35%)    WYNN (-3.5%)    XLE (-2.71%)    XLF (-2.77%)    XLU (0.73%)    XRX (-5.6%)    ZUO (-14.06%)    SQ (-4.39%)

 IMDZ - Immune Design Corp.

$5.85 [0.01][0.18%]

Next Earnings

3/29/2019

AMC

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

3


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $6.00
Low $6.00
Average $6.00
Current $5.85

CompanyAnalyst NamePT ActionActionRatingTargetDate
RBC CapitalLowersDowngradesHold$6.0002/22/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $IMDZ

TRENDING ARTICLES



The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie

02/25/19
For Immediate Release Chicago IL February 25 2019 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the

Merck to Buy Immunotherapy Developer Immune Design for $300M

02/23/19
Merck amp Co Inc MRK announced that it will acquire late stage immunotherapy company Immune Design IMDZ 160 for 300 million in cash Per the deal Merck through a subsidiary will acquire Immune Design for 5 85 per share in cash which represents a premium of 312 on Immune Design